We recommend using a newer internet browser, such as Google Chrome or Microsoft Edge, to optimize your browsing experience.

Skip to main content

Efficacy and Safety of Reslizumab in Pediatric Patients With Eosinophilic Asthma

- Eosinophilic Asthma
- Completed

Study Title: A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma

Teva Identifier: C38072/3082

ClinicalTrials.gov Identifier: NCT01287039

Study Status: Completed

Trial Condition(s): Eosinophilic Asthma

Interventions: Drug: Reslizumab | Drug: Placebo

Study Description: Please refer to ClinicalTrials.gov for a description of the trial

ClinicalTrials.gov study records with inclusion and exclusion criteria

Key Participation Requirements

Gender: Female, Male

Age Range: 12 Years to 75 Years

Trial Duration: 04/01/2011 - 03/01/2014

Phase: Phase 3

Study Type

Interventional